Anti β2-glycoprotein I antibodies: Clinical significance

A. Tincani, L. Spatola, M. Cinquini, R. Cattaneo, P. Meroni, G. Balestrieri

Research output: Contribution to journalArticle

Abstract

The introduction of anticardiolipin antibody (aCL) assay, described in 1983, was able to focus much attention on the study of patients suffering from thrombosis, repeated fetal loss and thrombocytopenia, and allowing the identification of the so called antiphospholipid syndrome (APS). The identification of β2 glycoprotein I (β2GPI) as an essential component of the antigenic complex recognized by aCL suggested that this molecule could be a direct target of the antibody response. Since then, different groups have described ELISAs for the detection of anti β2GPI antibodies, applied to the clinical evaluation of patients with APS, and showing an overall better specificity. Recently, anti β2GPI were also shown to bind apoptotic bodies resulting in an alteration of their physiological clearance with the triggering of TNFα release. This observation suggests that anti β2GPI may also modify the immunogenicity of apoptotic bodies and of the autoantigens that they contain.

Original languageEnglish
JournalLupus
Volume7
Issue numberSUPPL. 2
Publication statusPublished - 1998

Fingerprint

Glycoproteins
Anticardiolipin Antibodies
Antiphospholipid Syndrome
Antibodies
Autoantigens
Thrombocytopenia
Antibody Formation
Thrombosis
Enzyme-Linked Immunosorbent Assay
Extracellular Vesicles

Keywords

  • Anti-β-glycoprotein I antibodies
  • Antiphospholipid syndrome

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Tincani, A., Spatola, L., Cinquini, M., Cattaneo, R., Meroni, P., & Balestrieri, G. (1998). Anti β2-glycoprotein I antibodies: Clinical significance. Lupus, 7(SUPPL. 2).

Anti β2-glycoprotein I antibodies : Clinical significance. / Tincani, A.; Spatola, L.; Cinquini, M.; Cattaneo, R.; Meroni, P.; Balestrieri, G.

In: Lupus, Vol. 7, No. SUPPL. 2, 1998.

Research output: Contribution to journalArticle

Tincani, A, Spatola, L, Cinquini, M, Cattaneo, R, Meroni, P & Balestrieri, G 1998, 'Anti β2-glycoprotein I antibodies: Clinical significance', Lupus, vol. 7, no. SUPPL. 2.
Tincani A, Spatola L, Cinquini M, Cattaneo R, Meroni P, Balestrieri G. Anti β2-glycoprotein I antibodies: Clinical significance. Lupus. 1998;7(SUPPL. 2).
Tincani, A. ; Spatola, L. ; Cinquini, M. ; Cattaneo, R. ; Meroni, P. ; Balestrieri, G. / Anti β2-glycoprotein I antibodies : Clinical significance. In: Lupus. 1998 ; Vol. 7, No. SUPPL. 2.
@article{3e4e9318e6024ad199764b6fcb64726c,
title = "Anti β2-glycoprotein I antibodies: Clinical significance",
abstract = "The introduction of anticardiolipin antibody (aCL) assay, described in 1983, was able to focus much attention on the study of patients suffering from thrombosis, repeated fetal loss and thrombocytopenia, and allowing the identification of the so called antiphospholipid syndrome (APS). The identification of β2 glycoprotein I (β2GPI) as an essential component of the antigenic complex recognized by aCL suggested that this molecule could be a direct target of the antibody response. Since then, different groups have described ELISAs for the detection of anti β2GPI antibodies, applied to the clinical evaluation of patients with APS, and showing an overall better specificity. Recently, anti β2GPI were also shown to bind apoptotic bodies resulting in an alteration of their physiological clearance with the triggering of TNFα release. This observation suggests that anti β2GPI may also modify the immunogenicity of apoptotic bodies and of the autoantigens that they contain.",
keywords = "Anti-β-glycoprotein I antibodies, Antiphospholipid syndrome",
author = "A. Tincani and L. Spatola and M. Cinquini and R. Cattaneo and P. Meroni and G. Balestrieri",
year = "1998",
language = "English",
volume = "7",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Anti β2-glycoprotein I antibodies

T2 - Clinical significance

AU - Tincani, A.

AU - Spatola, L.

AU - Cinquini, M.

AU - Cattaneo, R.

AU - Meroni, P.

AU - Balestrieri, G.

PY - 1998

Y1 - 1998

N2 - The introduction of anticardiolipin antibody (aCL) assay, described in 1983, was able to focus much attention on the study of patients suffering from thrombosis, repeated fetal loss and thrombocytopenia, and allowing the identification of the so called antiphospholipid syndrome (APS). The identification of β2 glycoprotein I (β2GPI) as an essential component of the antigenic complex recognized by aCL suggested that this molecule could be a direct target of the antibody response. Since then, different groups have described ELISAs for the detection of anti β2GPI antibodies, applied to the clinical evaluation of patients with APS, and showing an overall better specificity. Recently, anti β2GPI were also shown to bind apoptotic bodies resulting in an alteration of their physiological clearance with the triggering of TNFα release. This observation suggests that anti β2GPI may also modify the immunogenicity of apoptotic bodies and of the autoantigens that they contain.

AB - The introduction of anticardiolipin antibody (aCL) assay, described in 1983, was able to focus much attention on the study of patients suffering from thrombosis, repeated fetal loss and thrombocytopenia, and allowing the identification of the so called antiphospholipid syndrome (APS). The identification of β2 glycoprotein I (β2GPI) as an essential component of the antigenic complex recognized by aCL suggested that this molecule could be a direct target of the antibody response. Since then, different groups have described ELISAs for the detection of anti β2GPI antibodies, applied to the clinical evaluation of patients with APS, and showing an overall better specificity. Recently, anti β2GPI were also shown to bind apoptotic bodies resulting in an alteration of their physiological clearance with the triggering of TNFα release. This observation suggests that anti β2GPI may also modify the immunogenicity of apoptotic bodies and of the autoantigens that they contain.

KW - Anti-β-glycoprotein I antibodies

KW - Antiphospholipid syndrome

UR - http://www.scopus.com/inward/record.url?scp=0032245796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032245796&partnerID=8YFLogxK

M3 - Article

C2 - 9814685

AN - SCOPUS:0032245796

VL - 7

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - SUPPL. 2

ER -